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DRUG FORMULARY COMMISSION 
MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH 
Henry I. Bowditch Public Health Council Room, 2nd Floor 
250 Washington Street, Boston MA 
 
 
Docket: Tuesday, September 8, 2015 9:00 AM 
 
 
1. ROUTINE ITEMS: 
 
a. Welcome and Opening Remarks 
 
b. Approval of the Minutes (Vote) 
 
c. Office of the General Counsel Update 
 
 
2. REVIEW OF DRUG FORMULARY COMMISSION: 
 
a. Commission’s Purpose 
 
b. Evaluation and Review Process 
 
c. Discussion of Stakeholder Engagement 
 
 
3. PRELIMINARY DISCUSSION OF EVALUATION CRITERIA: 
 
a. Heightened Public Health Risk Criteria  
 
b. Substitute Criteria 
a. Definition of Interchangeability  
b. Drugs with Current FDA Labeling 
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Drug Formulary Commission 
 
Presented below is a summary of the meeting, including time-keeping, attendance and votes cast.  
 
Date of Meeting: Tuesday, September 8, 2015 
Beginning Time:  9:05 AM 
Ending Time:   11:44 AM 
Attendance and Summary of Votes:  
 
Board Member Attended Minutes 
Dr. Dan Alford Absent Absent 
Dr. Douglas Brandoff Yes Yes 
Cheryl Campbell Absent Absent 
Ray Campbell III Yes Yes 
Dr. Daniel Carr Yes Yes 
Joanne Doyle-Petrongolo Yes Yes 
Stephen Feldman 
Yes Yes 
Dr. Kenneth Freedman Yes Yes 
Dr. Paul Jeffrey Yes Yes 
Virginia Lemay Absent Absent 
Eric Sheehan Yes Not voting 
Cindy Steinberg Yes Yes 
Dr. Jeffrey Supko Yes Yes 
Dr. Theoharis Theoharides Absent Absent 
Tammy Thomas Yes Yes 
Dr. Alexander Walker Yes Yes 
Summary 
12 
Members attended 
 
11 
Approved with votes 
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1. PROCEEDINGS 
 
A regular meeting of the Drug Formulary Commission (M.G.L. Ch. 17, § 13) was held on Tuesday, September 8, 2015 at the 
Massachusetts Department of Public Health, 250 Washington Street, Henry I. Bowditch Public Health Council Room, 2
nd
 Floor, 
Boston, Massachusetts 02108.  
 
Members present were:  Department of Public Health Interim Director of the Bureau of Health Care Safety and Quality, Eric 
Sheehan (Chair), Dr. Douglas Brandoff, Mr. Ray Campbell III, Dr. Daniel Carr, Dr. Joanne Doyle-Petrongolo, Mr. Stephen 
Feldman, Dr. Kenneth Freedman, Dr. Paul Jeffrey, Ms. Cindy Steinberg, Dr. Jeffrey Supko, Ms. Tammy Thomas, and Dr. 
Alexander Walker.   
 
Absent members were: Dr. Dan Alford, Ms. Cheryl Campbell, Dr. Virginia Lemay, and Mr. Theoharis Theoharides. 
 
Also in attendance were the following staff from the Department of Public Health: Attorney Rebecca Rodman, Deputy General 
Counsel; Suzanne Cray, Director of the Office of Health Care Integration at the Bureau of Health Care Safety and Quality; 
Jonathan Mundy, Director of the Office of Prescription Monitoring and Drug Control at the Bureau of Health Care Safety and 
Quality; and David Dunn, Associate Executive Director of the Board of Registration in Pharmacy. 
 
Interim Director Sheehan called the meeting to order at 9:05 AM and made opening remarks before reviewing the agenda and 
introductions. 
 
Interim Director Sheehan stated that he was representing Department of Public Health Commissioner Dr. Monica Bharel and 
will serve as her representative as Chair of the Drug Formulary Commission. Interim Director Sheehan thanked the members for 
attendance, and reminded them this is a public hearing and was being recorded. Interim Director Sheehan thanked the 
Commission members for their commitment and willingness to be a part of the fight against the opioid crisis in Massachusetts 
and across the nation, and he reiterated how important the Commission is to develop solutions aimed at preventing and 
treating addiction. He stated that the Baker-Polito Administration is dedicated to comprehensively addressing this public health 
issue, and the Commission is an important component of the plan to stop addiction. Interim Director Sheehan stated that the 
day would be spent going into detail on the Commission’s purpose and how the work ahead of this Commission is planned to 
be completed. Interim Director Sheehan announced that there was a new member of the Commission, and asked all the 
members to introduce themselves.  
 
Interim Director Sheehan asked if there were any changes to minutes from the August 6
th
 meeting, after which Ms. Steinberg 
corrected a statement on page 5 of the previous minutes, clarifying that physicians must take a 3 CEU course in opioid 
management every two years. Interim Director Sheehan then asked if there was a motion to vote to approve the minutes with 
this addition, and Dr. Paul Jeffrey motioned to approve the minutes, and Stephan Feldman seconded the motion for approval of 
the minutes. Interim Director Sheehan declared the minutes approved after a unanimous vote from all 11 voting members 
present.  
 
Interim Director Sheehan introduced Rebecca Rodman from the Office of General Counsel to provide updates from the 
previous meeting.  She stated that the Ethics Commission is the source to go to for conflict of interest law, and she can assist in 
giving guidance regarding the issues. Ms. Rodman also stated that there is legal protection for the Commission members during 
normal activity in their role in the Commission, and that if the need arises, the Attorney General’s office will defend the 
members, and the State will provide for the expenses of the legal fees and any punitive charges that may result from court. Ms. 
Rodman state she can be reached by email at Rebecca.Rodman@state.ma.us and phone at 617-994-9811.   
 
2. REVIEW OF THE DRUG FORMULARY COMMISION 
 
Interim Director Sheehan introduced the next section of the agenda- an overview of the Drug Formulary Commission.   The 
presentation will follow-up on items from the August 6 meeting and review the evaluation and review process that we will use 
to develop the draft formulary.   
 
Interim Director Sheehan began the presentation by stating how the members would complete the work. He stated that the 
Drug Formulary Commission continues to maintain the Massachusetts List of Interchangeable Drugs, and Chapter 258 of the 
Acts of 2014 enhanced the Commission’s role. The Commission is here to develop a formulary aimed at identifying Schedule II 
and III opioids that have heightened public risk and therapeutic substitutes for these drugs. This task will be completed in three 
components. 
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Interim Director Sheehan explained that these components were: 1. identify drugs that have a heightened public health risk, 2. 
identify possible therapeutic substitutes, 3. complete a “cross-walk” of these that will identify the substitutes for each drug with 
a heightened public health risk.  Interim Director Sheehan stated he knows this will be a significant task, and will take a 
tremendous amount of time will be needed from Commission members and DPH staff. However, it cannot be underestimated 
what an important task this Commission is undertaking to provide an additional tool to ending the opioid crisis in the 
Commonwealth. Interim Director Sheehan cited that last year it was estimated over 1,200 individuals died from an opiate 
overdose in MA, a 57% increase from 2012.  
 
Next, Interim Director Sheehan invited David Dunn, Associate Executive Director of the Board of Registration in Pharmacy of the 
Department of Public Health, to continue the overview presentation. 
 
Mr. Dunn’s presentation included information on other states’ response to the opioid crisis, key terms, an evaluation and 
review process overview, more in depth descriptions of the three components of the Commission’s task, and examples of what 
the final products of this Commission may look like.  
 
During the presentation, Mr. Dunn clarified that though Chapter 258 states that the Commission shall prepare a drug formulary 
of chemically equivalent substitutions, the Department is interpreting this to be therapeutically equivalent substitutions. The 
Department is responsible for interpreting statutory language and from our review, we believe that it was the intent of the 
legislation to identify therapeutically equivalent substitutes as opposed to chemically equivalent substitutes, so that there 
would be more potential options to use in the formulary.    
 
Interim Director Sheehan thanked Mr. Dunn for his presentation, and stated that the work that has been outlined is a 
significant undertaking and will require significant time and commitment of all members. He extended his gratitude and 
appreciation in advance of the work that must be completed. Interim Director Sheehan then started to discuss the timeline of 
tasks and meetings of the Commission to ensure that the statutory mandate is met. 
 
Interim Director Sheehan presented the timeline, and stated that because of the comprehensive process to develop the draft 
formulary and the need for significant discussion and deliberation, there will be two meetings per month from October through 
January. Time will be prioritized to focus on the most prescribed Schedule II drugs as these will likely trigger the most discussion 
and questions, but all of the Schedule II and III opioids will be considered. The short time-frame between meetings will also 
allow for the topic to be fresh in the minds of the Commission members, and DPH staff will assist in every way possible to make 
this timeline work for Commission members.  
 
Interim Director Sheehan stated that by February 18, 2016, the Commission will produce a full evaluation and vote on all 28 
Schedule II and III groups of drugs and determine which present a “heightened public health risk”. The four drugs with FDA 
abuse deterrent labeling will undergo a therapeutic substitution review, and the Commission will crosswalk the FDA labeled 
drugs as substitutes for the drugs with heightened public risk. That would achieve the legislative mandate of having an initial 
draft formulary completed.  Following this milestone, the Commission will start meeting on a monthly basis to build on the 
draft drug formulary. Interim Director Sheehan opened the floor for questions and feedback.  
 
Dr. Freedman asked for an email of all upcoming dates, as well as polling for when to meet on those dates.  Interim Director 
Sheehan stated that one should be sent out by the end of the week. 
 
Next, Interim Director Sheehan stated that he wants to make sure that the Commission has the most relevant, timely, and 
beneficial information available, which can be obtained from stakeholders and experts. To facilitate this process, the October 1 
meeting will be an information hearing.  Experts will be invited to testify and respond to specific questions that would most 
inform the work of the Commission members. Holding this meeting will also allow for the Commission to be transparent, 
allowing outside parties to share ideas and feedback.  
 
Interim Director Sheehan referred to a list describing the roles of experts that DPH staff plans to reach out to in the 
presentation. Each testifier will be asked to tailor their remarks to a small number of framing questions provided to them ahead 
of time.  Interim Director Sheehan then asked for the Commission members feedback regarding to who should be invited, and 
what questions should be responded to. 
 
Dr.  Doyle-Petrongolo states that the Commission already has experts in many of these areas. Interim Director Sheehan 
responded that having stakeholders and outside experts will bring even more expertise.    
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Dr. Carr stated that the FDA gives notice in advance of its meetings posted to a website, and stakeholders are allowed to ask for 
time at the meetings. He asks how the Commission plans on sending out the request. Interim Director Sheehan responded that 
DPH will solicit experts to come to the next meeting. Rebecca Rodman stated that the Department does not have a similar 
process to the FDA’s.  We will need to post the information on our website so stakeholders are aware.     
 
Dr. Jeffrey asked for clarification if these experts and stakeholders would be coming to the October 1 meeting, and Interim 
Director Sheehan responded that was correct. 
 
Interim Director Sheehan also mentioned that they will be asking for written statements from those who wish to present at the 
meeting but are unable to make it there.  
 
Dr. Supko asked if the individuals that will be asked to come have been identified yet. Interim Director Sheehan responded that 
just the groups of experts listed in the slides have been identified.  
 
Dr. Jeffrey followed up by asking if the Commission is responsible for constructing the questions that will be sent to the experts 
ahead of time. Interim Director Sheehan responded that yes, to maximize the time the Commission should develop specific 
questions to ask based on the area of expertise of the expert.  
 
Mr. Feldman asked what is off limits to this Commission, and stated that the stakeholders should be informed on what the 
Commission’s final product will look like. Interim Director Sheehan responded the questions posed to the stakeholders should 
be in line with the Commission’s mission.  We want to have the stakeholders involved early on, so they can provide information 
and data needed to complete the task. 
Dr. Walker stated that it may be helpful to hear from the same testifiers twice.  Maybe now and then again to make sure the 
Commission is on track.  
Mr. Campbell commented that some experts such as experts on public risk should be involved early in the process, then other 
experts may be more useful later on it the process, it does not need to be the same people speaking during both timeframes.  
Mr. Feldman asked if the questions for the individual experts will be given ahead of time. Interim Director Sheehan responded 
that yes, questions will be provided in advance to maximize time, and give them an idea of what to present.  
Dr. Freedman stated the first stakeholder meeting should be a general overview presentation, then they will need to come back 
at least one more time for specific. He wanted the invitees to receive a draft of the process so they know what the Commission 
is doing, allowing for transparency. He also stated that there likely will be a significant amount of presentations at the 
stakeholder meetings, and asked for a written transcript of all testimony and presentation material to be provided at this 
meeting. Interim Director Sheehan stated that the first stakeholder meeting will be in advance of voting on the evaluation 
criteria and give us an opportunity to review feedback prior to the October 15 meeting.  
Mr. Campbell asked if it was possible for the Commission to get feedback without quorum.  Is there a way to set up a series of 
hearings with as many members present as possible? He stated that needing quorum at the meeting where stakeholders are 
presenting may not be the best method to obtaining information; they should not always need quorum to get any information. 
Ms. Rodman responded that is difficult to have a meeting with Commission members present without it being considered an 
actual, public meeting, which would require quorum. When information is presented that is needed to make a final decision 
that would need to come during an official meeting.  
Ms. Steinberg proposed the idea of creating an open website where stakeholders can post or submit information to. Ms. 
Rodman responded that this is a good idea of how to receive information, just in person meeting of members would need to be 
official.  
Dr. Walker stated that he wants the experts to have input on the Commission’s method, and for the experts to show the 
Commission where they may go wrong. Interim Director Sheehan commented that all products of this meeting are public 
record, and can be reviewed by interested parties.  
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Dr. Feldman stated that we should frame what we are doing and how we will help address the opioid crisis.  If we are 
measuring just on the number of overdoses, that is a problem. Interim Director Sheehan responded that the formulary is just 
one tool, there are other groups working to address the issue.  
Dr. Doyle-Petrongolo stated she would like a summary of what the Commission is doing sent to stakeholders, and in terms of 
the questions to pose to testifiers, we should ask to determine how this list will affect patients, physicians, and other 
stakeholders. She also stated that outreach would likely need to be done to pharmacies and providers how this list can affect 
their practice. Dr. Doyle-Petrongolo also stated that the Commission will need to know about overdose rates and which drugs 
led to abuse, as well as the toxicology reports stating which drugs were present in the patients system (for example was heroin 
laced with fentanyl, or other harmful substances besides just schedule II and III  opioids). Interim Director Sheehan responded 
that DPH is still working on data requests from the previous meeting that may address this. 
3. PRELIMINARY DISCUSSION OF THE EVALUATION CRITERIA 
Interim Director Sheehan stated that we have discussed the process and timeline, the Commission will discuss the development 
of the criteria for determining if a drug group or individual drug should be considered as having a heightened public risk and 
which drugs would be the therapeutic substitutes. He wants to ensure there is a consistent standard review and that the same 
factors are applied to each drug and drug group. Interim Director Sheehan then introduced David Dunn to facilitate this 
discussion, so that the Commission may develop a strong draft of criteria that can be formalized after receiving stakeholder 
feedback. 
Dr. Carr stated that public risk and addiction potential were analyzed for federal scheduling of drugs, so drugs with heightened 
public risk may already be determined.  
Dr. Freedman stated the FDA has already determined these drugs are in Schedule II and III, so that should be the Commission’s 
guidance on heightened public risk. He stated that autopsy and toxicology reports of which drugs were present in a person’s 
system during overdose, as well as other drugs those patients were prescribed would be important information. Dr. Freedman 
also asked whether popularity and number of prescriptions determines heightened public risk- do those with the highest 
number of prescriptions result in a higher likelihood of abuse?  Mr. Dunn responded that DPH has the data requests from the 
first meeting, and is in the process of compiling those. He also stated that one of the most important data point will likely be 
high provider episodes (patients who are receiving these prescriptions from 5 or more prescribers).  
Mr. Campbell asked if all Schedule II are necessarily at a heightened public risk since they were classified into that schedule. He 
stated that component 2 of this Commission’s tasks will take a significant amount of time, so it may be beneficial to just assume 
all Schedule II and III opioids are of heightened public risk, allowing for component 1 to be completed quickly.  Interim Director 
Sheehan responded that this is something the Commission could vote on and make a determination. 
Dr. Jeffrey stated that these drugs were scheduled in Schedule II or III for a reason, and that means they are a heightened public 
risk, so all should be included on the list.  All are potentially able to be abused and we should consider substitutes for all.  
Dr. Walker stated that tramadol is not a schedule II or III drug, but it is a gateway drug, and users may take it to potentiate the 
effects of other opioids to give a cheaper more effective high. He stated that the Commission might want to consider that not 
all opioids at heightened public risk are schedule II or III. Interim Director Sheehan responded that the current mandate from 
the statute is to assess the Schedule II and III opioids, but that does not stop the Commission from addressing other schedules 
at a later date.  
Dr. Doyle-Petrongolo stated that it is important to address ways that users may circumvent this formulary, so considering other 
scheduled drugs is important. Interim Director Sheehan responded that the Commission still exists after this list is made, and 
can address this topic.  
Dr. Walker added that as well as multiple provider episodes it also would be important to consider multiple pharmacy episodes.  
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Mr. Feldman stated that they need the quantity of prescriptions, because abusers will want as many pills as possible. If the 
quantity and days supply is known, it can be compared to standards of care to determining who is getting more of these drugs 
than medically necessary. 
Dr. Brandoff stated that although all schedule II and III opioids may have abuse potential, they also do have clinical benefits 
when used correctly. He stated that to determine heightened public risk need to address the heterogeneity of this problem, the 
drugs cannot be looked at in a vacuum, you need to consider context. We need to consider what these drugs mean to people.    
Dr. Freedman commented that it would be useful to know the drugs associated with ER visits for overdose.  Does it drill down 
to which opiates an individual was taking at the time of overdose? 
Dr. Jeffrey stated that the drugs used in combination with opioids (such as benzodiazepines, Soma, gabapentin, etc) also play a 
role in the pattern of abuse and misuse, so the frequency that these are taken with opioids would be helpful to know.  
Dr. Freedman stated that the correlation between high pharmacy and physician use may show the abuse of other non-opioid 
medications as well. 
Mr. Feldman stated that diagnostic information also needs to be considered, because in some cases such as cancer patients, a 
high volume prescription would be acceptable, but not in other patients who may not have any medical diagnosis. Dr. Brandoff 
added that co-morbid conditions are also important to consider as well as the diagnosis of the episode being treated with the 
prescription.  
Interim Director Sheehan stated that it seems like the Commission may have come to the consensus that all schedule II and III 
opioids should be considered at a heightened public risk. This will be brought up at a future meeting, and for now, the 
Commission should move on to component 2 of its task. 
Mr. Dunn discussed the measures of efficacy that this Commission will use to determine substitutes.  
In addition to the manufacturer data listed as a measure of efficacy, Dr. Feldman stated the Commission should also consider 
an independent research conducted on these drugs. Dr. Supko stated that all FDA approved data from trials should be 
considered useful and available. Dr. Jeffrey proposed adding health economic and outcomes research, as well as real world 
studies of medications also be added to the list of information to consider efficacy.  
Dr. Supko noted that the statute indicates that the substitution being considered should be between drugs with the same 
chemical entity only. Interim Director Sheehan responded that therapeutic equivalence is the standard being used by this 
Commission, so chemical equivalence is not necessary.  
Mr. Dunn described the effectiveness of abuse deterrent properties. Ms. Steinberg asked for clarification if this Commission will 
use FDA criteria for labelling as abuse deterrent as part of our substitution criteria. Mr. Dunn responded that yes, we will be 
using that in consideration for the criteria.  Interim Director Sheehan clarified that the Commission has the statutory ability to 
approve the four drugs that are already labelled as abuse deterrent by the FDA to be considered substitutes on the formulary 
without going through the criteria. 
Dr. Jeffrey asked if the Commission can consider drugs that do not meet the FDA requirements for labelling. When he read the 
statute, he thought we would be limited.  Attorney Rodman clarified that there are drugs being considered by the FDA that 
have not yet been granted the FDA label but they should be considered.   
Dr. Carr asked whether a patient will just migrate to drugs that do not have an abuse deterrent alternative, and will the abuse 
deterrent properties actually lower abuse? He then stated that in the FDA guidance on abuse deterrence it mentioned that 
drugs with a slower rise in plasma concentration have less abuse potential, but it may not always be smart to switch to drugs 
with slower concentration increases when these drugs may have other toxicities, such as methadone and meperidine. 
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Mr. Feldman stated that it would be important for the Commission to determine a measure of how effective it is in addressing 
the opioid crisis. The public may look at overdose rates to measure this, but that may not give an accurate view of whether or 
not this Commission is having an effect on the opioid crisis.  
Dr. Jeffrey stated that there is lots of post-marketing surveillance data that is conducted as “real world studies” that may help 
to determine effectiveness.   
Dr. Supko asked for clarification on the charge of the Commission.  The statute says chemically equivalent- are we going to 
follow the statute? Interim Director Sheehan stated that although the statute says chemically equivalent, the intent is to use 
therapeutically equivalent.   
Dr. Walker asked if that would leave the Commission open to legal challenge.  Ms. Rodman responded that the statute says 
chemically equivalent in one place, but later the statute directs the Commission to include drugs that have been deemed to be 
therapeutically equivalent. The Department is charged with interpreting the statute as appropriate, and has determined that an 
appropriate substitution does not mean only drugs that are chemically equivalent, but also drugs that are therapeutically 
equivalent.   
Dr. Carr stated that the notion of what is an equivalent is an important topic and we don’t want to overstep in terms of patient 
access.  
Mr. Mundy stated that the ultimate substitution list this Commission produces is not a mandate, but is a guide to advise the 
prescriber if there is a concern of abuse.  It will be a tool and advisory piece of information for providers to use it they think 
abuse is possible, and gives the pharmacy the ability to substitute these drugs provided that the prescriber does not indicate 
dispense as written on the prescription. 
Dr. Feldman voiced his concern about ensuring that the product of this Commission does not affect patients who are well-
controlled pain programs, and that avoiding switching medications that are working for a patient is important.  
Interim Director Sheehan concluded the agenda item, and stated that Commission members should be prepared to continue 
this discussion at the meetings on October 1 and 15, with the goal of evaluating drugs at the November 2 meeting. 
Interim Director Sheehan thanked the Commission and asked for a motion to adjourn. Mr. Campbell motioned to adjourn, and 
Dr. Walker seconded the motion. All members voted to adjourn. The meeting was adjourned at 11:44 AM.  
 
  
LIST OF DOCUMENTS PRESENTED TO THE DRUG FORMULARY COMMISSION FOR THIS MEETING: 
1. Docket of the meeting. 
2. Copies of the power point presentation (posted online upon conclusion of the meeting). 
3. Copies of the August 6, 2015 draft minutes. 
 
 
Interim Director Eric Sheehan, Chair  
 
 
